PMID- 37214201 OWN - NLM STAT- MEDLINE DCOM- 20230524 LR - 20230524 IS - 1742-1241 (Electronic) IS - 1368-5031 (Print) IS - 1368-5031 (Linking) VI - 2022 DP - 2022 TI - Efficacy of Exenatide Administered Twice Daily in Body Mass Index Reduction in Patients with Type 2 Diabetes Mellitus. PG - 7128859 LID - 10.1155/2022/7128859 [doi] LID - 7128859 AB - BACKGROUND: Exenatide is a glucagon-like peptide-1 receptor agonist that can reduce body weight. This study aimed to determine the efficacy of exenatide on body mass index (BMI) reduction in patients with type 2 diabetes mellitus (T2DM) with differing baseline body weight, blood glucose, and atherosclerotic status and to determine if there is a correlation between BMI reduction and cardiometabolic indices in these patients. METHODS: This retrospective cohort study used data from our randomized controlled trial. A total of 27 T2DM patients treated with combination therapy of exenatide twice daily and metformin for 52 weeks were included. The primary endpoint was a change in the BMI from the baseline to week 52. The secondary endpoint was a correlation between BMI reduction and cardiometabolic indices. Findings. The BMIs of overweight and obesity patients and those with glycated hemoglobin (HbA1c) >/= 9% significantly decreased -1.42 +/- 1.48 kg/m(2)(P=0.015) and -0.87 +/- 0.93 kg/m(2)(P=0.003), respectively, at the baseline after 52 weeks of treatment. There was no reduction in BMI in patients with normal weight, HbA1c <9%, the nonatherosclerosis group, and the atherosclerosis group. The decrease in BMI was positively correlated with changes in blood glucose, high-sensitivity C-reactive protein (hsCRP), and systolic blood pressure (SBP). CONCLUSION: BMI scores improved after exenatide treatment for 52 weeks in T2DM patients. Weight loss was affected by baseline body weight and blood glucose level. In addition, BMI reduction from the baseline to 52 weeks was positively correlated with baseline HbA1c, hsCRP, and SBP. Trial Registration. Chinese Clinical Trial Registry (ChiCTR-1800015658). CI - Copyright (c) 2022 Jie Zhang et al. FAU - Zhang, Jie AU - Zhang J AUID- ORCID: 0000-0002-6958-7562 AD - Department of Endocrinology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Graduate School of Peking Union Medical College, Beijing 100730, China. FAU - Xian, Tong-Zhang AU - Xian TZ AD - Department of Endocrinology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Graduate School of Peking Union Medical College, Beijing 100730, China. FAU - Teng, Yu AU - Teng Y AD - Central Laboratory, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing, China. FAU - Wang, Xiuzhi AU - Wang X AD - Department of Endocrinology, Pinggu Hospital, Beijing Traditional Chinese Medicine Hospital, Beijing 100006, China. FAU - Wu, Ming-Xiao AU - Wu MX AD - Department of Ultrasound, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing 100730, China. FAU - Li, Chen AU - Li C AD - Department of Ultrasound, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing 100730, China. FAU - Wang, Weihao AU - Wang W AUID- ORCID: 0000-0002-5896-2793 AD - Department of Endocrinology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Graduate School of Peking Union Medical College, Beijing 100730, China. FAU - Man, Fuli AU - Man F AD - Department of Endocrinology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Graduate School of Peking Union Medical College, Beijing 100730, China. FAU - Zhang, Xianbo AU - Zhang X AD - Department of Endocrinology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Graduate School of Peking Union Medical College, Beijing 100730, China. FAU - Wang, Xiaoxia AU - Wang X AUID- ORCID: 0000-0002-2077-3743 AD - Department of Endocrinology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Graduate School of Peking Union Medical College, Beijing 100730, China. FAU - Guo, Li-Xin AU - Guo LX AUID- ORCID: 0000-0001-6863-1798 AD - Department of Endocrinology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Graduate School of Peking Union Medical College, Beijing 100730, China. LA - eng PT - Journal Article PT - Randomized Controlled Trial DEP - 20221010 PL - India TA - Int J Clin Pract JT - International journal of clinical practice JID - 9712381 RN - 9P1872D4OL (Exenatide) RN - 0 (Hypoglycemic Agents) RN - 0 (Blood Glucose) RN - 0 (Glycated Hemoglobin) RN - 9007-41-4 (C-Reactive Protein) RN - 0 (Venoms) SB - IM MH - Humans MH - Exenatide/adverse effects MH - *Diabetes Mellitus, Type 2/complications MH - Body Mass Index MH - Hypoglycemic Agents/adverse effects MH - Blood Glucose/metabolism MH - Glycated Hemoglobin MH - Retrospective Studies MH - C-Reactive Protein MH - Body Weight MH - Weight Loss MH - *Cardiovascular Diseases/chemically induced MH - Venoms/therapeutic use PMC - PMC10199797 COIS- The authors declare that they have no conflicts of interest. EDAT- 2023/05/22 19:11 MHDA- 2023/05/24 06:42 PMCR- 2022/10/10 CRDT- 2023/05/22 12:08 PHST- 2022/04/03 00:00 [received] PHST- 2022/08/29 00:00 [accepted] PHST- 2023/05/24 06:42 [medline] PHST- 2023/05/22 19:11 [pubmed] PHST- 2023/05/22 12:08 [entrez] PHST- 2022/10/10 00:00 [pmc-release] AID - 10.1155/2022/7128859 [doi] PST - epublish SO - Int J Clin Pract. 2022 Oct 10;2022:7128859. doi: 10.1155/2022/7128859. eCollection 2022.